-
Wave Life Sciences’ obesity siRNA shows “once or twice-yearly” potential
30 Oct 2025 19:04 GMT
Wave Life Sciences’ siRNA obesity drug has shown promise in … dose cohorts suggesting the drug could lead to stronger … unsolicited bid to acquire obesity drug developer Metsera, which had … making it unsurprising that major pharma companies are battling to make …
-
Antisense & RNAi Therapeutics Market to Reach USD 17.74 Billion by 2032, Driven by Gene-Silencing Breakthroughs
30 Oct 2025 13:20 GMT
… drug innovations, gene-silencing breakthroughs, and advanced RNA therapeutics research. Driven by siRNA … As gene-silencing therapeutics expand into oncology, neurology, and rare genetic … pipelines, and rising pharma–biotech collaborations. The sector shows …
-
Codexis and Nitto Denko Avecia Enter Evaluation Agreement to Explore Codexis's ECO Synthesis® Manufacturing Platform for Therapeutic siRNA Manufacturing
29 Oct 2025 21:59 GMT
… (CDMO) specializing in oligonucleotide therapeutics, today announced that they have … advancing scalable and sustainable therapeutic siRNA manufacturing. About Codexis, Inc. … -manufacturing-platform-for-therapeutic-sirna-manufacturing-302598473.html SOURCE …
-
Recursion gets $30M from Roche; Chinese siRNA biotech to go public in Hong Kong
29 Oct 2025 18:20 GMT
-
GSK licences siRNA COPD drug in US$745m biobucks deal
28 Oct 2025 14:54 GMT
… is a highly selective siRNA candidate that modulates key … .
First-in-class siRNA pipeline
EMP-012 represents … therapies for COPD:
Silence Therapeutics: siRNA candidates targeting inflammatory pathways … a first-in-class siRNA targeting an unmet pathophysiological …
-
GSK forges pact with Empirico for respiratory siRNA in $745m deal
29 Oct 2025 14:17 GMT
… RNA (siRNA), EMP-012.
The UK-based big pharma purchased the … is a first-in-class siRNA that targets an undisclosed, … Illinois-based pharma’s $1.4bn acquisition of Aliada Therapeutics in 2024 … total deal value of innovator drug licensing agreements signed with …
-
GSK’s Respiratory Pipeline Adds an Early-Stage Drug Offering a Novel Approach to COPD
29 Oct 2025 00:41 GMT
… small-interfering RNA (siRNA) therapies. Drugs in this class of … is “backed by extensive genetic data and translational insight, … an early-stage Hengrui Pharma COPD drug candidate designed to block … of inhaled and biologic therapeutics in this area of …
-
Diabetic Retinopathy Market Size Worth USD 17.91 Billion by 2034
30 Oct 2025 12:35 GMT
… is the acquisition of smaller biotech firms with promising pipeline candidates … and develops small interfering RNA (siRNA) therapeutics that target specific genes to … driving diabetic care innovation ➡️ Ophthalmic Drugs Market: Explore how novel formulations …
-
New trick could stop lung cancer in its tracks
29 Oct 2025 20:53 GMT
… put tiny pieces of genetic material called siRNA into lung cancer cells … to harness EVs as a drug delivery system so that new … cancer drugs can target cancer cells without … pieces of siRNA into modified EVs. These snippets of genetic code …
-
Harnessing extracellular vesicles for targeted lung cancer treatment
29 Oct 2025 19:49 GMT
… put tiny pieces of genetic material called siRNA into lung cancer cells … to harness EVs as a drug delivery system so that new … cancer drugs can target cancer cells without … pieces of siRNA into modified EVs. These snippets of genetic code …
About
© 1995-2025